SV

Street Verdict

Analyst Scorecard

A record of what Nuvama Analysis said publicly, with the source. Not advice.

“Nuvama maintains a 'BUY' rating on Divi's Laboratories with an unchanged target price of ₹6,830. The company outperformed Q3FY25 consensus estimates for revenue, EBITDA, and PAT, with a robust EBITDA margin of 32%. Expansion of product portfolio and client base, particularly GLP-1, are key growth drivers.”

Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%

Divi's LaboratoriesBullishCalled 04 Feb 2025Graded 01 Jul 2025
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹6,830, as stated.

Window: 12 months, the default when no time frame is stated.

The target ₹6,830 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹6123.5 on 2025-02-05 (next trading session's close); target ₹6830 reached at close ₹6856.5 on 2025-07-01. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Divi's Laboratories since this call

1-year tracking window
Read the original articleSee Nuvama Analysis’s full track record